FilingReader Intelligence
Jiuzhou Pharma subsidiary passes US FDA inspection
August 12, 2025 at 05:08 PM UTC•By FilingReader AI
R&D Suzhou, a subsidiary of Zhejiang Jiuzhou Pharmaceutical, passed a U.S. FDA inspection from May 19-22, 2025. The company received a "No Action Indicated" result, confirming compliance with FDA requirements for three APIs including Entresto and Kisqali.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SSE:603456•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Zhejiang Jiuzhou Pharmaceutical publishes news
Free account required • Unsubscribe anytime